Kids & teens (for parents) · Arkansas
Studies for children and teens in Arkansas
These studies only enroll people under 18. A parent or legal guardian gives permission, and children old enough to understand are asked for their own agreement (assent).
35 recruiting studiesSource: ClinicalTrials.gov, refreshed October 26, 2026How we list studies
Studies
- RecruitingHealthy volunteers
Extensively Hydrolyzed Formula Growth Monitioring Study (GMS)
Mead Johnson Nutrition
- Location
- Jonesboro, AR + 9 other US sites
- Eligibility basics
- Ages 0 mo–0 mo
- RecruitingHealthy volunteersPhase 3
A Study to Learn About How a New Pneumococcal Vaccine Works in Infants.
Pfizer
- Location
- Fayetteville, AR + 101 other US sites
- Eligibility basics
- Ages 1 mo–7 mo
- RecruitingHealthy volunteersPhase 3
Lot-to-lot Consistency Study of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From 2 Months of Age
Sanofi
- Location
- Fayetteville, AR + 13 other US sites
- Eligibility basics
- Ages 1 mo–2 mo
- RecruitingHealthy volunteersPhase 3
A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine When Given to Healthy Children 12 to 15 Months of Age
GlaxoSmithKline
- Location
- Hot Springs, AR + 46 other US sites
- Eligibility basics
- Ages 1–1
- RecruitingPhase 3
A Surveillance Study of Susceptibility to Baloxavir Marboxil in Pediatric Participants With Influenza and Transmission of Influenza to Household Contacts
Hoffmann-La Roche
- Location
- Harrisburg, AR + 10 other US sites
- Eligibility basics
- Ages 1 mo–11
- RecruitingPhase 1/Phase 2
PBGENE-DMD Phase 1/2a Safety and Preliminary Efficacy Study in Duchenne Muscular Dystrophy (FUNCTION-DMD)
Precision BioSciences, Inc.
- Location
- Little Rock, AR + 1 other US site
- Eligibility basics
- Ages 2–7 · Men only
- RecruitingPhase 3
A Long-term Study of the Medicine Called Abrocitinib in Children Aged 2 Years and Older With Moderate to Severe Eczema
Pfizer
- Location
- North Little Rock, AR + 6 other US sites
- Eligibility basics
- Ages 2–11
- RecruitingPhase 3
Forward Treatment of Attention Deficit and Hyperactivity Using Solriamfetol (FOCUS-2)
Axsome Therapeutics, Inc.
- Location
- Little Rock, AR + 28 other US sites
- Eligibility basics
- Ages 6–11
- RecruitingPhase 3
Forward Treatment of Attention Deficit and Hyperactivity Using Solriamfetol (FOCUS-3)
Axsome Therapeutics, Inc.
- Location
- Little Rock, AR + 27 other US sites
- Eligibility basics
- Ages 12–17
- RecruitingPhase 3
A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years
AbbVie
- Location
- Little Rock, AR + 28 other US sites
- Eligibility basics
- Ages 12–17
- RecruitingPhase 2
A Study to Assess the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of Intravenous Administration of ARGX-119 in Pediatric Participants Aged 5 to Less Than 18 Years With Spinal Muscular Atrophy
argenx
- Location
- Little Rock, AR + 10 other US sites
- Eligibility basics
- Ages 5–17
- RecruitingPhase 2
This is a Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study of the Efficacy and Safety of 2 Weight-based Treatment Groups of Plecanatide Versus Placebo in Children and Adolescent…
Bausch Health Americas, Inc.
- Location
- Hot Springs, AR + 22 other US sites
- Eligibility basics
- Ages 6–17
- RecruitingPhase 3
A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine
AbbVie
- Location
- Little Rock, AR + 25 other US sites
- Eligibility basics
- Ages 6–17
- RecruitingPhase 4
Evaluation of SPN-812 (Viloxazine Extended-release Capsule) in Preschool-age Children With ADHD
Supernus Pharmaceuticals, Inc.
- Location
- Little Rock, AR + 38 other US sites
- Eligibility basics
- Ages 4–5
- RecruitingPhase 4
A Study Evaluating the Effectiveness and Safety of Risdiplam Administered as an Early Intervention in Pediatric Participants With Spinal Muscular Atrophy After Gene Therapy
Hoffmann-La Roche
- Location
- Little Rock, AR + 9 other US sites
- Eligibility basics
- Ages 4 mo–2
- RecruitingPhase 4
Safety and Tolerability of Open-Labeled Iloperidone in Adolescents
Vanda Pharmaceuticals
- Location
- Little Rock, AR + 9 other US sites
- Eligibility basics
- Ages 12–17
- RecruitingPhase 3
Safety and Tolerability Trial of Lumateperone in Pediatric Patients With Schizophrenia, Bipolar Disorder or Autism Spectrum Disorder
Intra-Cellular Therapies, Inc.
- Location
- Little Rock, AR + 46 other US sites
- Eligibility basics
- Ages 5–17
- RecruitingPhase 3
Multicenter Study of Lumateperone for the Treatment of Bipolar Depression in Pediatric Patients
Intra-Cellular Therapies, Inc.
- Location
- Little Rock, AR + 33 other US sites
- Eligibility basics
- Ages 10–17
- RecruitingPhase 3
Multicenter Study of Lumateperone for the Treatment of Irritability Associated With Autism Spectrum Disorder (ASD) in Pediatric Patients
Intra-Cellular Therapies, Inc.
- Location
- Little Rock, AR + 26 other US sites
- Eligibility basics
- Ages 5–17
- RecruitingPhase 3
A Study of the Medicine Called Abrocitinib in Children 6 to Less Than 12 Years of Age With Moderate-to-Severe Eczema
Pfizer
- Location
- North Little Rock, AR + 12 other US sites
- Eligibility basics
- Ages 6–11
- RecruitingPhase 3
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)
AbbVie
- Location
- Glenwood, AR + 87 other US sites
- Eligibility basics
- Ages 6–17
- RecruitingPhase 3
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo
Incyte Corporation
- Location
- Fayetteville, AR + 65 other US sites
- Eligibility basics
- Ages 2–11
- Recruiting
GAINS Expert Guiding Technology to Coach Life Skill Teaching
Guiding Technologies Corporation
- Location
- Fayetteville, AR
- Eligibility basics
- Ages 3–10
- RecruitingPhase 3
A Study to Assess Adverse Events, Change in Disease Activity, and How the Drug Moves Through the Body in Children With Juvenile Psoriatic Arthritis (jPsA) Receiving Subcutaneously Injected Risankizumab or Adalimumab
AbbVie
- Location
- Little Rock, AR + 11 other US sites
- Eligibility basics
- Ages 5–17